Here is another co. that I think is pretty promising. Remember to do your own research and make your own decision.
There is another thread..though not too active..on SI but I thought I would create a new one to put down I what know from my research.
EXTI's (Exten) only business venture currently is in its wholly owned subsidiary called Xenogenics which owns a technology for developing a machine that acts like a dialysis machine for the liver. Apparently, such machine does not exists right now so if they are successfully in aquiring FDA approval, and marketing it there is a huge payoff, especially there stock at current low prices in the pennies. One use is while a patient is awaiting on a donar they can use this machine to fill the gap since the person cannot survive more than few days without the liver. There are other clinical uses for the machine.
EXTI has developed such a machine and is currently awaiting private placement to initiate Phase I of clinical trials. Sounds like any other startup biotech company at this point. But the thing that impressed me is the people they put together to get this machine off the ground. They have eight, or so, memembers in there recently formed Scientific advisory board and all of them appear to have solid credentials, and affiliated with major medical centers (like Loyola and Yale), and all are directors of liver transplant for the insititutions. Get there names from prior press releases, as well as on their web page (exten.com), then do a Yahoo search and you will see some articles and interivews of these peopole in various publications. These people sound solid in liver transplant and give credence to this co. One interesting web page I found was a hepatitis organizaton which mentioned EXTEN in their recent technology development section - a very short article but at least it was not a stock promoting web site. Combined with them is the CEO of EXTEN who appears to have a solid business expertise particulary in starup and turnaround companies. It's the management team that I am inmpressed with and it looks like they have solid people to get the trials going.
I recently called the co. and was not able to talk to the CEO, but the intern i talked to (they have one full time staff to do PR work aside from company officers, the intern sounds like a non-paid student)said they already have done the study on animals ( I am not sure if this is part of PhaseI or not)...and they are just awiting on financing.
You can check out their SEC filings...but it doesn't do much as they have the standard horrible financials and nearly non-existing cash. No surprise here given .03/share price. I think outstnading shares is around 30M - at least it isn't 100M. THIS IS A VERY HIGH RISK PLAY AND I WOULD NOT USE ANY MONEY YOU CAN'T LOSE but at .03-.04 to get in now imagine it going up to .5 would be a 10x bagger.
DISCLAIMER - THIS IS ALL MY OPINION. PLEASE DO YOUR OWN RESEARCH AND MAKE YOUR OWN DECISIONS. |
